re e-tender (2nd call) for procurement of some drug items under table-a, for two years from the date of aoc. , plasma derived factor viii (500 iu./ 250 iu.) /vial , recombinant anti hemophilic factor viiiwith extended half life ( ehl) (pegylated/glyco-pegylated) 1000 iu / vial , recombinant anti hemophilic factor viiiwith extended half life ( ehl) (pegylated/glyco-pegylated) 500 iu / vial , recombinant anti hemophilic factor viii 1000 iu./vial , recombinant anti hemophilic factor viii 250 iu./vial , trastuzumab emtansine inj. 100mg per vial/pfs , important note: 1. all prospective bidders are requested to quote the rate in boq as per accounting unit & item specification as mentioned in the table-a. wrong quoting of the rate in boq will be dealt with as per penal provisions of the t&c of the tender. 2. quality of the product supplied, may be ascertained by testing / physical examination by the experts at any stage of the tender period. 3. the prospective bidders of the said tender are requested to make a declaration in affidavit under annexure vi(b)in case of sole manufacturer/importer (i.e. proprietary in nature). 4. if the item(s) under sole manufacturer / importer is (are) proprietary in nature, quarterly intimation is solicited from the approved bidders positively regarding the status of their item(s) proprietary in nature, otherwise their item(s) will be blocked in the smis. 5. in case of tie bid, decision will be taken by the tia as per g.o. no. 2320-f(y), dated 07.06.2022 issued from finance department audit branch (group t).